Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.67 |
| ▸ | HTR2A | P28223 | 1/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.67 |
| ▸ | HRH1 | P35367 | 1/20 | 0.67 |
| ▸ | HTR2B | P41595 | 1/20 | 0.67 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.67 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.65 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 4/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5831539 | 0.97 | SLC6A2 (0.64) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL5708352 | 0.97 | SLC6A2 (0.64) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL5079223 | 0.84 | GFER (0.50) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL10875275 | 0.83 | HTR2A (0.59) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL10891421 | 0.82 | SLC6A2 (0.64) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL562858 | 0.82 | SLC6A2 (0.64) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL564834 | 0.81 | SLC6A2 (0.63) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL22591635 | 0.81 | ALDH1A1 (0.52) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL861221 | 0.81 | ESR1 (0.61) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL25342534 | 0.80 | SLC6A2 (0.61) | SLC6A2HTR2ASLC6A4HRH1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1577288-B1 | Selective estrogen receptor modulators | EISAI R&D MAN CO LTD (JP) | 2014-07-23 | — | — | EP | disclosed |
| EP-1747208-B1 | NOVEL SUSTAINED-ACTION BRONCHODILATING AGENTS FOR USE IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2013-09-25 | — | — | EP | disclosed |
| US-8399520-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20120071654-A1 | ARYL ANILINE DERIVATIVES AS BETA2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | RADIUS HEALTH, INC. | 2012-01-05 | — | — | US | disclosed |
| US-7994165-B2 | Aryl aniline derivatives as β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-7960412-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| EP-1706371-B1 | ARYL ANILINE DERIVATIVES AS BETA2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE INC (US) | 2011-04-06 | — | — | EP | disclosed |
| US-7745621-B2 | Long acting bronchodilators for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-29 | — | — | US | disclosed |
| US-20100087410-A1 | ARYL ANILINE DERIVATIVES AS BETA2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| EP-0757674-A1 | SUBSTITUTED SULFONAMIDES AS SELECTIVE $g(b) 3? AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | Merck & Co., Inc. (US) | 1997-02-12 | — | — | EP | disclosed |
| US-5561142-A | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity | MERCK & CO., INC. (US) | 1996-10-01 | — | — | US | disclosed |
| US-5541197-A | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity | MERCK & CO., INC. (US) | 1996-07-30 | — | — | US | disclosed |
| WO-1995029159-A1 | SUBSTITUTED SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | MERCK & CO., INC. (US) | 1995-11-02 | — | — | WO | disclosed |
| US-4894219-A | ADRENERGIC BLOCKING AGENTS, ANALYZING | UNIVERSITY OF FLORIDA (US) | 1990-01-16 | — | — | US | disclosed |
| US-4433137-A | MOLDING MATERIALS | CIBA-GEIGY CORPORATION (US) | 1984-02-21 | — | — | US | disclosed |
| US-4429110-A | HYDROLYTICALLY STABLE MOLDING MATERIALS | CIBA-GEIGY CORPORATION (US) | 1984-01-31 | — | — | US | disclosed |
| US-4376125-A | Aminobenzlpropranolol and pharmaceutical preparation thereof | UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) | 1983-03-08 | — | — | US | disclosed |
| US-4024185-A | REDUCTION OF AROMATIC DINITRO COMPOUNDS | ALLIED CHEMICAL CORPORATION (US) | 1977-05-17 | — | — | US | disclosed |
| US-3776890-A | POLYAMIDES FROM 2-(4-AMINOCYCLOHEXYL)-1,1-DIMETHYLETHYLAMINE OR 2-(4-AMINO-PHENYL)-1,1-DIMETHYLETHYLAMINE | ALLIED CHEM | 1973-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071654-A1 | ARYL ANILINE DERIVATIVES AS BETA2 ADRENERGIC RECEPTOR AGONISTS | ADRB2, ADRB1, ADRA2A | SLC6A2 119/4885HTR2A 46/4885SLC6A4 737/4885 |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | ESR1, GPER1, ESR2 | SLC6A2 4107/4885HTR2A 1377/4885SLC6A4 3550/4885 |
| US-20100087410-A1 | ARYL ANILINE DERIVATIVES AS BETA2 ADRENERGIC RECEPTOR AGONISTS | ADRB2, ADRB1, ADRA2A | SLC6A2 119/4885HTR2A 46/4885SLC6A4 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.